Alkermes sees positive results with schizophrenia drug

This is a summary. To read the whole story subscribe to

Alkermes PLC was a bright spot among the biotechs — the sector has been more than a bit volatile lately — after the company said its experimental drug to treat schizophrenia symptoms, aripiprazole lauroxil, met the main goal in a late-stage study. Patients treated once a month with either 441 or 882 milligrams had statistically significant improvement. Alkermes plans to seek FDA approval in the third quarter. Based in Dublin, Alkermes has its R&D center in Waltham.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.